Progesterone vs Progestins: Why the Distinction Matters for Your Health

Progesterone vs progestins: what’s the difference? Progesterone and progestins (sometimes referred to as progestogens in the UK) are different molecules with different effects on the body, but the terms are used interchangeably in clinical practice, leaving many women believing they are taking the same thing. They are not. 

Progestins are synthetic compounds designed to activate progesterone receptors, primarily in the uterus, but they do not replicate progesterone’s wider effects on mood, sleep, metabolism, cardiovascular health, breast tissue and long-term disease risk. Which one you are prescribed matters, particularly when it comes to contraception, fertility treatment and HRT.

What is progesterone?

Progesterone is a natural steroid hormone produced primarily by the ovaries after ovulation and in large amounts during pregnancy. Smaller amounts are also synthesised in the adrenal glands and within the brain itself. In clinical practice, progesterone is usually prescribed as oral micronised progesterone, sometimes referred to as body-identical or bioidentical progesterone. This formulation is chemically identical to the hormone produced by the ovaries, therefore is able to produce all the benefits of progesterone too.

Progesterone acts as a whole-body hormone. It prepares the uterus for implantation and supports pregnancy, but it also regulates sleep, stress responses, immune balance, body temperature, bone formation and breast tissue development. Because progesterone is highly fat soluble, it readily crosses cell membranes and enters tissues throughout the body, including the brain.

Read about causes of low progesterone here. 

Progesterone metabolites

A key feature of progesterone is that it is metabolised (the pathway progesterone takes in order to leave the body) into two main urinary metabolites: alpha-pregnanediol (a-Pregnanediol) and beta-pregnanediol (b-Pregnanediol). a-Pregnanediol is especially important as it leads to the formation of allopregnanolone, a neurosteroid with anti-inflammatory and calming effects. Allopregnanolone interacts with GABA-A receptors and influences mood, anxiety, sleep and stress regulation.

What are progestins (progestogens)?

Progestins, also known as progestogens in the UK, are synthetic compounds designed to activate progesterone receptors, particularly in the uterus. They are widely used in hormonal contraception, fertility treatment and hormone therapy.

Common examples include levonorgestrel, norethisterone, medroxyprogesterone acetate, desogestrel and drospirenone. These molecules are structurally different from progesterone and interact not only with progesterone receptors but also with androgen, glucocorticoid and mineralocorticoid receptors.

This means progestins behave more like pharmacological agents than physiological hormones. Their effects extend beyond the reproductive system and vary widely depending on their chemical structure.

Importantly, most synthetic progestins do not undergo the same metabolic conversion as natural progesterone. They are not reliable substrates for the 5α pathway and are not converted into allopregnanolone or related neuroactive steroids. Instead, they are metabolised through hepatic cytochrome P450 pathways into compounds that lack the calming and neuroprotective properties of progesterone metabolites.

This metabolic difference has major functional consequences for the brain and nervous system.

Progesterone vs progestins: key differences in the body

Let’s look at some of the differences that progesterone vs progestins (progestogens) have on the whole body.

1. Breast health and cancer risk

One of the most clinically important differences in progesterone vs progestins lies in breast tissue.

Progesterone regulates normal mammary cell differentiation and limits excessive estrogen-driven proliferation. Observational studies and meta-analyses consistently suggest that oestrogen combined with natural progesterone is associated with lower breast cancer risk than oestrogen combined with synthetic progestins.

In contrast, large trials such as the Women’s Health Initiative, demonstrated increased breast cancer risk with oestrogen plus medroxyprogesterone acetate (a progestin). This increased risk was not seen with oestrogen alone or in cohorts using micronised progesterone (real progesterone).

2. Mood, sleep and the nervous system

Progesterone’s influence on the brain is largely mediated through its conversion into allopregnanolone. This neurosteroid supports an anti-stress, anti-anxiety and relaxing, sedative impact on the brain. This pathway is one reason progesterone is often associated with improved sleep quality and emotional regulation in many women.

However, not all women respond to progesterone in the same way. Hormonally sensitive individuals, particularly those with premenstrual dysphoric disorder (PMDD), for example can experience that the rapid changes in progesterone can worsen mood. This reflects altered brain sensitivity to neurosteroids rather than abnormal hormone levels.

Synthetic progestins lack this neurosteroid pathway. They do not reliably support GABA signalling and may instead alter hypothalamic-pituitary-adrenal (HPA) axis activity, increasing cortisol reactivity. Large observational studies have consistently found higher rates of depression and anxiety in users of certain progestin-based contraceptives, particularly levonorgestrel-containing intrauterine systems and oral formulations.

This helps explain why many women feel emotionally different on synthetic hormones compared to natural progesterone.

For women with neuropsychiatric vulnerability, including ADHD, anxiety disorders or sleep disturbances, these differences may be especially important. Progesterone’s neuroactive metabolites can support calmness and sleep regulation, whereas some progestins may exacerbate emotional dysregulation in sensitive individuals.

3. Cardiovascular effects and blood clot risk

Natural progesterone appears to support vascular health. It promotes endothelial relaxation, reduces arterial stiffness and has mild diuretic effects. Micronised progesterone does not significantly increase blood pressure or cardiovascular disease risk in menopausal hormone therapy.

Synthetic progestins show more variable effects. Some increase blood pressure, alter lipid profiles and promote fluid retention. Certain oral progestins, particularly medroxyprogesterone acetate, are associated with higher cardiovascular risk in older women.

Both progesterone and progestins can slightly increase the risk of venous thromboembolism when combined with estrogen, but large epidemiological studies indicate that micronised progesterone carries a lower thrombotic risk than many synthetic progestins.

4. Metabolism and weight gain

Progesterone plays a role in glucose regulation, insulin sensitivity and energy balance. It slightly increases metabolic rate and supports healthy fat distribution. Although appetite often increases in the luteal phase of the menstrual cycle, progesterone itself does not appear to promote long-term weight gain.

Progestins show a less favourable metabolic profile. Some increase insulin resistance, promote central fat accumulation and influence appetite through androgenic activity. Weight gain is one of the most frequently reported side effects of progestin-based contraception and is more consistently observed than with natural progesterone.

5. Skin, hair and androgen effects

Progesterone has mild anti-androgenic activity and supports normal skin barrier function and hair follicle cycling.

Several progestins are androgenic and may worsen acne, increase facial hair or contribute to scalp hair thinning. Levonorgestrel, for example, is chemically closer to testosterone than to progesterone, which helps explain its androgenic side effects.

Other progestins such as drospirenone are anti-androgenic and may improve acne. Again, outcomes depend entirely on the specific molecule used.

6. Immune system and inflammation

Progesterone has immunomodulatory properties. It suppresses excessive inflammatory responses, increases regulatory immune cell activity and supports tissue repair. Many autoimmune conditions improve during pregnancy when progesterone levels are high.

Synthetic progestins do not consistently reproduce these effects and may increase inflammatory markers depending on their receptor activity.

7. General side effects 

Common side effects of micronised progesterone include sleepiness, dizziness, breast tenderness and bloating. These effects are largely dose-related and often improve when progesterone is taken at night.

Progestins are more commonly associated with mood changes, reduced libido, acne, headaches, weight gain, emotional blunting and irregular bleeding. While not every woman experiences these effects, they are biologically well documented.

Progesterone vs progestins: a clinical perspective

Both progesterone and progestins protect the endometrium when oestrogen is prescribed, and when appropriately dosed, appear similarly effective at preventing abnormal thickening of the uterine lining. However, comparative outcome data favour progesterone for breast health, metabolic risk and cardiovascular safety. Progestins remain clinically valuable where strong endometrial suppression or reliable contraception is required.

The distinction is particularly relevant during perimenopause, when progesterone levels tend to decline first and symptoms such as anxiety, brain fog and poor sleep often emerge. In this context, natural progesterone offers benefits for the brain and body that synthetic progestins do not.

Want to understand your own hormone levels?

FUTURE WOMAN’s Advanced Hormone Test measures progesterone and its metabolites alongside oestrogen, androgens, adrenal hormones, inflammation markers and nutrient status, giving a detailed picture of where you are in your hormonal journey. 

For those considering HRT, our specialist bHRT clinic combines in-depth testing with expert prescribing to build a treatment plan tailored to you.

References 

Asi, N., Mohammed, K., Haydour, Q., Gionfriddo, M. R., Vargas, O. L., Prokop, L. J., Faubion, S. S., & Murad, M. H. (2016). Progesterone vs. synthetic progestins and the risk of breast cancer: A systematic review and meta-analysis. Systematic Reviews, 5(1), 121. https://doi.org/10.1186/s13643-016-0294-5

Baulieu, E. E., & Robel, P. (1990). Neurosteroids: A new brain function? Journal of Steroid Biochemistry and Molecular Biology, 37(3), 395–403. https://doi.org/10.1016/0960-0760(90)90490-C

Belelli, D., & Lambert, J. J. (2005). Neurosteroids: Endogenous regulators of the GABA(A) receptor. Nature Reviews Neuroscience, 6(7), 565–575. https://doi.org/10.1038/nrn1703

Fournier, A., Berrino, F., & Clavel-Chapelon, F. (2008). Unequal risks for breast cancer associated with different hormone replacement therapies. Breast Cancer Research and Treatment, 107(1), 103–111. https://doi.org/10.1007/s10549-007-9523-x

Frye, C. A., & Walf, A. A. (2004). Progesterone, its metabolites and neurosteroid effects on behavior. Brain Research Reviews, 46(2), 134–147. https://doi.org/10.1016/j.brainresrev.2004.04.001

Gompel, A., & Plu-Bureau, G. (2018). Progesterone, progestins and the breast in menopause hormone therapy. Climacteric, 21(4), 326–332. https://doi.org/10.1080/13697137.2018.1476483

Melcangi, R. C., Panzica, G. C., & Garcia-Segura, L. M. (2011). Neuroactive steroids: Focus on human brain. Neuroscience, 191, 1–5. https://doi.org/10.1016/j.neuroscience.2011.06.024

Prior, J. C. (2018). Progesterone for symptomatic perimenopause treatment. Gynecological Endocrinology, 34(6), 443–446. https://doi.org/10.1080/09513590.2018.1441867

Reddy, D. S. (2010). Neurosteroids: Endogenous role in the human brain and therapeutic potentials. Progress in Brain Research, 186, 113–137. https://doi.org/10.1016/B978-0-444-53630-3.00008-7

Sitruk-Ware, R. (2004). Progestogens in hormonal replacement therapy. Menopause, 11(1), 6–15. https://doi.org/10.1097/01.GME.0000075504.11345.5E

Stute, P., Wildt, L., & Neulen, J. (2018). The impact of micronized progesterone on the endometrium. Climacteric, 21(4), 321–325. https://doi.org/10.1080/13697137.2018.1468524

Vinogradova, Y., Coupland, C., & Hippisley-Cox, J. (2019). Use of hormone replacement therapy and risk of venous thromboembolism. BMJ, 364, k4810. https://doi.org/10.1136/bmj.k4810